AU2021205326B2 - SMARCA2-VHL degraders - Google Patents
SMARCA2-VHL degradersInfo
- Publication number
- AU2021205326B2 AU2021205326B2 AU2021205326A AU2021205326A AU2021205326B2 AU 2021205326 B2 AU2021205326 B2 AU 2021205326B2 AU 2021205326 A AU2021205326 A AU 2021205326A AU 2021205326 A AU2021205326 A AU 2021205326A AU 2021205326 B2 AU2021205326 B2 AU 2021205326B2
- Authority
- AU
- Australia
- Prior art keywords
- compound
- mmol
- carcinomas
- pharmaceutically acceptable
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062959502P | 2020-01-10 | 2020-01-10 | |
| US62/959,502 | 2020-01-10 | ||
| PCT/US2021/012683 WO2021142247A1 (en) | 2020-01-10 | 2021-01-08 | Smarca2-vhl degraders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2021205326A1 AU2021205326A1 (en) | 2022-07-21 |
| AU2021205326B2 true AU2021205326B2 (en) | 2026-06-11 |
Family
ID=74495106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021205326A Active AU2021205326B2 (en) | 2020-01-10 | 2021-01-08 | SMARCA2-VHL degraders |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230091042A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4087658B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7706456B2 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021205326B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3167166A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022008487A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021142247A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3737666A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES |
| US12454520B2 (en) | 2018-07-06 | 2025-10-28 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| US12624044B2 (en) | 2019-06-10 | 2026-05-12 | Kymera Therapeutics, Inc. | SMARCA degraders and uses thereof |
| WO2020251972A1 (en) | 2019-06-10 | 2020-12-17 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
| WO2021133917A1 (en) | 2019-12-23 | 2021-07-01 | Kymera Therapeutics, Inc. | Smarca inhibitors and uses thereof |
| US11679109B2 (en) | 2019-12-23 | 2023-06-20 | Kymera Therapeutics, Inc. | SMARCA degraders and uses thereof |
| MX2023001445A (es) * | 2020-08-04 | 2023-05-08 | Aurigene Oncology Ltd | Compuestos de piridazina 6-sustituidos como degradadores de smarca2 y/o smarca4. |
| US12606568B2 (en) | 2020-12-09 | 2026-04-21 | Kymera Therapeutics, Inc. | SMARCA degraders and uses thereof |
| JP2024533990A (ja) | 2021-08-09 | 2024-09-18 | ジェネンテック, インコーポレイテッド | Brmの調節に使用するためのフェノール誘導体 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019207538A1 (en) * | 2018-04-26 | 2019-10-31 | Aurigene Discovery Technologies Limited | Pyridazine derivatives as smarca2/4 degraders |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10519152B2 (en) | 2017-12-21 | 2019-12-31 | Astrazeneca Ab | Compounds and their use in treating cancer |
| AU2019249849C1 (en) * | 2018-04-01 | 2022-09-29 | Arvinas Operations, Inc. | BRM targeting compounds and associated methods of use |
| WO2019213005A1 (en) * | 2018-04-30 | 2019-11-07 | Dana-Farber Cancer Institute, Inc. | Small molecule degraders of polybromo-1 (pbrm1) |
-
2021
- 2021-01-08 CA CA3167166A patent/CA3167166A1/en active Pending
- 2021-01-08 US US17/788,272 patent/US20230091042A1/en active Pending
- 2021-01-08 WO PCT/US2021/012683 patent/WO2021142247A1/en not_active Ceased
- 2021-01-08 JP JP2022541815A patent/JP7706456B2/ja active Active
- 2021-01-08 AU AU2021205326A patent/AU2021205326B2/en active Active
- 2021-01-08 MX MX2022008487A patent/MX2022008487A/es unknown
- 2021-01-08 EP EP21702829.9A patent/EP4087658B1/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019207538A1 (en) * | 2018-04-26 | 2019-10-31 | Aurigene Discovery Technologies Limited | Pyridazine derivatives as smarca2/4 degraders |
Also Published As
| Publication number | Publication date |
|---|---|
| JP7706456B2 (ja) | 2025-07-11 |
| WO2021142247A1 (en) | 2021-07-15 |
| JP2023510746A (ja) | 2023-03-15 |
| US20230091042A1 (en) | 2023-03-23 |
| MX2022008487A (es) | 2022-08-02 |
| EP4087658A1 (en) | 2022-11-16 |
| CA3167166A1 (en) | 2021-07-15 |
| AU2021205326A1 (en) | 2022-07-21 |
| EP4087658B1 (en) | 2026-07-01 |